DK0855999T3 - 1-(1,2-disubstituerede piperidinyl)-4-substituerede piperidinderivater som tachykininreceptorantagonister - Google Patents

1-(1,2-disubstituerede piperidinyl)-4-substituerede piperidinderivater som tachykininreceptorantagonister

Info

Publication number
DK0855999T3
DK0855999T3 DK96944691T DK96944691T DK0855999T3 DK 0855999 T3 DK0855999 T3 DK 0855999T3 DK 96944691 T DK96944691 T DK 96944691T DK 96944691 T DK96944691 T DK 96944691T DK 0855999 T3 DK0855999 T3 DK 0855999T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
substituted piperidine
piperidine derivatives
tachykinin receptor
disubstituted piperidinyl
Prior art date
Application number
DK96944691T
Other languages
Danish (da)
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Dominique Louis Nest Surleraux
Roosbroeck Yves Emiel Mari Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0855999(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0855999T3 publication Critical patent/DK0855999T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK96944691T 1995-12-27 1996-12-20 1-(1,2-disubstituerede piperidinyl)-4-substituerede piperidinderivater som tachykininreceptorantagonister DK0855999T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203651 1995-12-27
PCT/EP1996/005883 WO1997024324A1 (en) 1995-12-27 1996-12-20 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
DK0855999T3 true DK0855999T3 (da) 2002-01-21

Family

ID=8221023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96944691T DK0855999T3 (da) 1995-12-27 1996-12-20 1-(1,2-disubstituerede piperidinyl)-4-substituerede piperidinderivater som tachykininreceptorantagonister

Country Status (29)

Country Link
US (2) US6169097B1 (xx)
EP (1) EP0855999B1 (xx)
JP (1) JP4039691B2 (xx)
KR (1) KR100493574B1 (xx)
CN (1) CN1131854C (xx)
AR (1) AR005277A1 (xx)
AT (1) ATE206397T1 (xx)
AU (1) AU707037B2 (xx)
BR (1) BR9612334A (xx)
CA (1) CA2238818C (xx)
CZ (1) CZ296316B6 (xx)
DE (1) DE69615700T2 (xx)
DK (1) DK0855999T3 (xx)
EA (1) EA001559B1 (xx)
ES (1) ES2164939T3 (xx)
HK (1) HK1011205A1 (xx)
HU (1) HU228128B1 (xx)
IL (1) IL124640A (xx)
MY (1) MY117557A (xx)
NO (1) NO310913B1 (xx)
NZ (1) NZ325843A (xx)
PL (1) PL192397B1 (xx)
PT (1) PT855999E (xx)
SI (1) SI0855999T1 (xx)
SK (1) SK283555B6 (xx)
TR (1) TR199801211T2 (xx)
TW (1) TW531537B (xx)
WO (1) WO1997024324A1 (xx)
ZA (1) ZA9610885B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032486A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ES2198948T3 (es) 1998-08-25 2004-02-01 Novartis Ag Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
AU2056800A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
CA2366260A1 (en) * 1999-03-05 2000-09-14 Masahiro Imoto Heterocyclic compounds having effect of activating .alpha.4.beta.2 nicotinic acetylcholine receptors
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CA2387535A1 (en) * 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
CA2413245A1 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6720325B2 (en) 2001-03-29 2004-04-13 Schering Corporation CCR5 antagonists useful for treating aids
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
ES2258642T3 (es) * 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
EP1720874A4 (en) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
CA2589001A1 (en) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
MX2007010728A (es) 2005-03-03 2007-10-12 Janssen Pharmaceutica Nv Derivados sustituidos de oxa-diaza-espiro-[5.5]-undecanona y su uso como antagonistas de la neurocinina.
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
ATE533744T1 (de) 2006-05-19 2011-12-15 Wyeth Llc N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2747677C (en) * 2008-12-19 2017-05-09 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
WO2010096703A1 (en) * 2009-02-19 2010-08-26 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
MY160471A (en) 2009-12-17 2017-03-15 Centrexion Therapeutics Corp New ccr2 receptor antagonists and uses thereof
WO2011119701A1 (en) * 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
MX2017017177A (es) 2015-07-02 2018-11-09 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona.
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
AR114810A1 (es) * 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
WO1993014083A1 (en) * 1992-01-09 1993-07-22 Janssen Pharmaceutica N.V. Pharmaceutically active substituted benzimidazole derivatives
TW397831B (en) 1994-07-15 2000-07-11 Meiji Seika Kaisha The anti-platelet-agglutination hexahydrogenated pyridine and its derivatives
ATE212981T1 (de) 1994-09-30 2002-02-15 Novartis Erfind Verwalt Gmbh 1-acyl-4-aliphatische aminopiperidin verbindungen
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives

Also Published As

Publication number Publication date
WO1997024324A1 (en) 1997-07-10
NO982404D0 (no) 1998-05-27
KR100493574B1 (ko) 2006-05-26
IL124640A (en) 2002-05-23
CN1206406A (zh) 1999-01-27
CZ296316B6 (cs) 2006-02-15
JP4039691B2 (ja) 2008-01-30
SK283555B6 (sk) 2003-09-11
CA2238818A1 (en) 1997-07-10
US6169097B1 (en) 2001-01-02
SK83198A3 (en) 1999-02-11
PT855999E (pt) 2002-03-28
ATE206397T1 (de) 2001-10-15
MY117557A (en) 2004-07-31
AR005277A1 (es) 1999-04-28
CZ186498A3 (cs) 1998-12-16
US6346540B1 (en) 2002-02-12
CA2238818C (en) 2006-10-17
EP0855999A1 (en) 1998-08-05
EA199800604A1 (ru) 1998-12-24
NO310913B1 (no) 2001-09-17
NZ325843A (en) 1999-05-28
HUP9904125A2 (hu) 2000-06-28
JP2000502690A (ja) 2000-03-07
AU707037B2 (en) 1999-07-01
NO982404L (no) 1998-08-19
HU228128B1 (hu) 2012-12-28
ZA9610885B (en) 1998-06-23
HK1011205A1 (en) 1999-07-09
TR199801211T2 (xx) 1998-09-21
DE69615700D1 (de) 2001-11-08
IL124640A0 (en) 1998-12-06
KR19990076716A (ko) 1999-10-15
HUP9904125A3 (en) 2002-03-28
SI0855999T1 (en) 2001-12-31
EA001559B1 (ru) 2001-04-23
TW531537B (en) 2003-05-11
ES2164939T3 (es) 2002-03-01
PL192397B1 (pl) 2006-10-31
BR9612334A (pt) 1999-03-02
PL327441A1 (en) 1998-12-07
AU1308497A (en) 1997-07-28
EP0855999B1 (en) 2001-10-04
CN1131854C (zh) 2003-12-24
DE69615700T2 (de) 2002-09-05

Similar Documents

Publication Publication Date Title
DK0855999T3 (da) 1-(1,2-disubstituerede piperidinyl)-4-substituerede piperidinderivater som tachykininreceptorantagonister
DK0862566T3 (da) 1-(1,2-Disubstitueret piperidinyl)-4-substituerede piperazindeivater
DK0804419T3 (da) Quinolinderivater som tachykinin NK 3-receptor-antagonister
DE69531331D1 (de) Phenylpiperidinderivate als neurokinin antagonists
NZ307625A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
DK0843679T3 (da) 1-(1,2-disubstitueret piperidinyl)-4-(kondenseret midazol)-piperidinderivater
TR199600930A2 (tr) Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür.
NO963984D0 (no) Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer
DK0869955T3 (da) N-acyl-2-substituerede-4-(benzimidazolyl- eller midazopyridinyl- substituerede grupper)-piperidiner som tachykinin-antagonister
DK0815105T3 (da) Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister
IT1277329B1 (it) Procedimento per la metilazione del 2,2,6,6-tetrametil-4-piperidone (triacetonammina)
NO943101D0 (no) 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
NO20005756L (no) Karboksysubstituerte karboksamidderivater som tachykininantagonister
IL120313A0 (en) Piperidine derivatives as neurokinin antagonists
ZA9610894B (en) 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives.